Genentech exec, three Caremark execs acquitted in Medicare/Medicaid Protropin kickback trial.
GENENTECH EXEC, THREE CAREMARK EMPLOYEES ACQUITTED of all charges in the Medicare/Medicaid anti-remuneration trial by Minneapolis federal court Judge David Doty Oct. 3. Genentech VP-Sales & Marketing Edmon Jennings and Caremark VPs James Mieszala and Joseph Herring and General Manager Judy Giel were cleared of the Minnesota U.S. Attorney's August 1994 charges that they had provided kickbacks to physicians in exchange for prescribing Genentech's Protropin human growth hormone ("The Pink Sheet" Aug. 8, 1994, p. 3).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth